B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astellas Pharma Inc (OP: ALPMY )

14.88 -0.28 (-1.85%)
Streaming Delayed Price Updated: 3:59 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 60,626
Open 14.73
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 15.16
Today's Range 14.73 - 14.90
52wk Range 12.82 - 17.96
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
 
Via Benzinga
What Is Going on With Taysha Gene (TSHA) Stock Today?
Taysha and its new partner Astellas are both speculating that Adeno Associated Viruses can create treatments for genetic diseases. 
Via InvestorPlace

Performance

YTD
-2.23%
-2.23%
1 Month
-1.85%
-1.85%
3 Month
+7.36%
+7.36%
6 Month
-3.94%
-3.94%
1 Year
-7.86%
-7.86%

More News

Read More
Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs
Via Benzinga
Astellas' Menopause Drug Under FDA Review
Via Benzinga
Seagen Shares Jump On Positive Data From Urothelial Cancer Trial
Via Benzinga
7 Best Biotech Stocks to Buy in July 2022
Via InvestorPlace
Sutro Biopharma Stock Surges On Cancer Treatment Pact
Via Benzinga
Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold
Via Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Via Benzinga
Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies
Via Benzinga
Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer
Via Benzinga
Astellas' Menopause Drug Suffers Setback After Failed Asian Trial
Via Benzinga
Astellas Touts Safety Data For Phase 3 Menopause Drug, Sets Up US Filing
Via Benzinga
Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients
Via Benzinga
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
Via Benzinga
4 No-Brainer Pharmaceutical Stocks to Buy in October
Via Talk Markets
Exposures COVID-19
Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan
Via Benzinga
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Via Benzinga
Exposures COVID-19
See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial
Via Benzinga
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Via Benzinga
Here's What Recent News From the FDA Means for AstraZeneca
Via The Motley Fool
Exposures Product Safety
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Via Benzinga
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.